Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
26.17 USD 0.00% Intraday chart for Surmodics, Inc. -1.21% -28.01%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Barrington Trims Price Target on SurModics to $70 From $71, Keeps Outperform Rating MT
Needham Adjusts SurModics' Price Target to $47 From $44, Maintains Buy Rating MT
Surmodics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Transcript : Surmodics, Inc., Q1 2024 Earnings Call, Feb 01, 2024
(SRDX) SURMODICS Forecasts Fiscal Year 2024 Revenue Range $117M - $121M MT
Earnings Flash (SRDX) SURMODICS Reports Q1 Revenue $30.6M, vs. Street Est of $29.6M MT
Earnings Flash (SRDX) SURMODICS Reports Q1 EPS $0.00, vs. Street Est of $-0.30 MT
Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024 CI
Surmodics, Inc. Announces Successful Early Clinical Use of its Pounce LP Thrombectomy System CI
Surmodics, Inc. Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium CI
Surmodics, Inc. Announces 24-Month Data from the Swing Trial Presented At VEITHsymposium CI
Barrington Ups Price Target on SurModics to $71 From $69 After Better-than-Expected Q4/23 Results, Keeps Outperform Rating MT
Transcript : Surmodics, Inc., Q4 2023 Earnings Call, Nov 08, 2023
(SRDX) SURMODICS Expects Fiscal Year 2024 Revenue Range $116M - $121M MT
Earnings Flash (SRDX) SURMODICS Reports Q4 Revenue $28M, vs. Street Est of $26.3M MT
Earnings Flash (SRDX) SURMODICS Reports Q4 EPS $0.53, vs. Street Est of $0.17 MT
Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024 CI
Surmodics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Surmodics, Inc. Provides Earnings Guidance for the Year 2024 CI
Surmodics, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023 CI
Surmodics, Inc. Announces Swing Trial 24-Month Data to Be Presented At Veith Symposium on November 15 CI
Surmodics, Inc. Announces Launch of Preside Medical Device Coating Technology, Providing Lubricity and Durability to a Broader Range of Complex Device Applications CI
Surmodics, Inc.(NasdaqGS:SRDX) added to S&P Healthcare Equipment Select Industry Index CI
Tranche Update on Surmodics, Inc.'s Equity Buyback Plan announced on November 6, 2014. CI
Transcript : Surmodics, Inc., Q3 2023 Earnings Call, Aug 02, 2023
Chart Surmodics, Inc.
More charts
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company's segments include Medical Device and IVD. The Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral, coronary and structural heart. It manufactures vascular intervention medical devices, including drug-coated balloons, and radial access balloon catheters and guide sheaths. The IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
26.17 USD
Average target price
59 USD
Spread / Average Target
+125.45%
Consensus
  1. Stock Market
  2. Equities
  3. SRDX Stock
  4. News Surmodics, Inc.
  5. Barrington Trims Price Target on SurModics to $70 From $71, Keeps Outperform Rating